FRIDAY, Sept. 5, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has created a "green list" import alert to stop unapproved and unverified glucagon-like peptide 1 (GLP-1) drug ingredients from entering the United States.
GoodRx reports tips for safely switching between GLP-1 medications due to side effects, insurance changes, or treatment goals.
GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain FDA approval by 2026.
Researchers found after bariatric procedures, patients lost an average of 58 pounds after two years, compared to 12 pounds for patients who received a GLP-1 prescription.
GoodRx says that with the support of a healthcare team, a clear transition plan, and a few cost-saving tools, you can make the process of switching from a compounded GLP-1 to a brand-name GLP-1 smoother, safer, and more affordable.